The Duke Human Vaccine Institute (DHVI) has been given approval to launch a Phase 1 clinical trial of one of its most promising antibody treatments for COVID-19. This would be a temporary treatment until a vaccine is developed. The DHVI also is developing a pan-coronavirus vaccine that would combat future iterations of COVID-19 and similar viruses, and also researching if saliva can be used as an accurate indicator of COVID-19 infection.